arrow
M

Maite G. Fernández-Barrena

hepatology laboratory
H指数:39
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unveiling the role of age in MASLD development and biological process activation: Implications for translational research

揭示年龄在MASLD发展及生物过程激活中的作用:对转化研究的启示

2026-08-220
PRE
Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma

三叶因子-3是缺氧诱导的肝母细胞瘤促肿瘤因子

2026-03-130
OAAI
Demonstration of SLU7 as a new cancer target

SLU7作为新的癌症靶点的验证

2025-12-020
OAAI
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway

NEDD8特异性蛋白酶1缺乏通过CAND1-NEDD8通路失调作为肝母细胞瘤发展的新型驱动因素

2025-11-010
PRE
Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot Study

原发性硬化性胆管炎中胆汁游离DNA的突变分析: 一项初步研究

2025-04-010
OAAI
FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis
2025-01-270
OAAI
Quantitative proteomic analysis unveils a critical role of VARS1 in hepatocellular carcinoma aggressiveness through the modulation of MAGI1 expression

定量蛋白质组学分析揭示VARS1通过调节MAGI1表达在肝细胞癌侵袭性中发挥关键作用

2025-01-140
OA
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)
2024-10-040
OA
Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

肝细胞癌中全面的计算机CpG甲基化分析可识别与基因表达无关的组织和肿瘤类型特异性标记

2024-09-210
OAAI
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
2023-10-0118
OA
A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

一种新的FGF15/19介导的肠-心轴控制心脏肥大

2023-08-314
OAAI